AC Immune SA filings document a foreign private issuer developing precision therapeutics and diagnostics for neurodegenerative diseases. Recent Form 6-K reports furnish press releases, IFRS financial statements, management discussion and annual statutory and compensation reports, with certain reports incorporated by reference into Form F-3 and Form S-8 registration statements.
The disclosures cover clinical and trial updates for ACI-24, ACI-7104.056, ACI-19764 and ACI-35.030/JNJ-2056; collaboration amendments for Morphomer® Tau small molecules; cash resources and operating requirements; and governance-related compensation reporting. They also record exhibit-based material updates for AC Immune’s active immunotherapy, small-molecule and diagnostic pipeline.
AC Immune SA (ACIU) shareholders elected Tom Graney to the Board of Directors at an Extraordinary General Meeting held October 2, 2026. His term runs until the end of the Annual General Meeting 2027. AC Immune said the meeting minutes would be published on its website within 15 days.
AC Immune SA reported safety and immunogenicity results through week 100 in Part 1 of its Phase 2 VacSYn trial of ACI-7104 in early-stage Parkinson’s disease. All primary endpoints—safety, tolerability and immunogenicity—were met; the study included 34 patients, with 25 receiving ACI-7104 and nine receiving placebo. The company reported a 100% antibody response after three immunizations and antibody penetration into cerebrospinal fluid.
Exploratory analyses found a signal in total α-synuclein in cerebrospinal fluid, described as preliminary evidence consistent with target engagement. Part 1 was not designed to evaluate biomarkers or clinical outcomes. The trial continues in a two-year extension, and Part 2 is advancing toward initiation; its design is being consolidated for FDA review, with meetings expected in early 2027.
AC Immune SA (ACIU) has called an Extraordinary General Meeting on October 2, 2026 to vote on electing Tom Graney to the Board of Directors for a term lasting until the 2027 AGM. Subject to his election, the Board intends to appoint him to the Audit and Finance Committee and considers him independent under Swiss corporate governance standards.
The meeting follows recent R&D updates, including FDA Fast Track designation for ACI-7104 for early Parkinson’s disease, initial Phase 1 results for NLRP3 inhibitor ACI-19764, and continued development of ACI-24 in Alzheimer’s disease with Takeda. Board member Carl June will step down from the Board and the Audit and Finance Committee effective as of the EGM, with the company stating his decision is not due to any disagreement.
AC Immune SA (ACIU) reported positive interim results from a first-in-human Phase 1/1b trial of ACI-19764, its wholly owned, orally administered small-molecule inhibitor of the NLRP3 inflammasome. In healthy volunteers, ACI-19764 was safe and well tolerated across single and multiple ascending dose cohorts, including single doses up to 20mg per day, with a serum half-life greater than 30 hours, no serious adverse events and no treatment withdrawals. Cerebrospinal fluid data showed clear brain penetration, and daily doses at or below 10mg achieved pharmacokinetic concentrations above the IC90 with dose-dependent inhibition of IL‑1β release. A Phase 1b cohort in patients with cardiovascular risk, defined by elevated hsCRP plus type 2 diabetes and/or obesity, is now dosing, with initial results expected by year end and full Phase 1/1b data expected in the first half of 2027.
AC Immune SA reports that the U.S. FDA has granted Fast Track designation and cleared the IND application for its wholly owned anti‑alpha‑synuclein active immunotherapy ACI‑7104 for early‑stage Parkinson’s disease. ACI‑7104 is designed to induce alpha‑synuclein‑specific antibodies that preferentially recognize aggregated, neuron‑toxic species.
The therapy is being evaluated in the adaptive, biomarker‑based VacSYn Phase 2 trial, with final Part 1 week‑100 results expected in H2 2026. Interim Part 1 data at 76 weeks showed ACI‑7104 was safe and well tolerated, achieved a 100% immunogenicity responder rate, and provided early signals of activity. A $4 million research grant from the Vijay and Marie Goradia Charitable Foundation supports extending Part 1 for an additional two years to assess long‑term safety and efficacy.
AC Immune SA reported first-half 2026 contract revenue of CHF 16.2 million, up from CHF 2.3 million mainly from Takeda and Lilly milestones, while IFRS net loss narrowed to CHF 12.9 million versus CHF 40.2 million a year earlier.
Research and development expenses declined to CHF 22.2 million after 2025 portfolio prioritization, and operating cash outflow improved to CHF 15.6 million. Liquidity totaled CHF 75.4 million in cash and short‑term financial assets, which the company believes will be sufficient to meet projected operating requirements through Q4 2027.
Collaboration activity was strong: a USD 12 million Takeda milestone for the ABATE trial and CHF 11.0 million from a Lilly Tau Morphomer amendment drove revenue, and short‑term deferred contract revenue reached CHF 89.5 million. Wholly owned programs ACI‑7104 and ACI‑19764 are expected to deliver Phase 2 and Phase 1 data in H2 2026.
AC Immune reported interim 12‑month data from the first three prodromal Alzheimer’s disease cohorts (AD1–AD3) of the Phase 1b/2 ABATE trial, covering 74 patients treated with its anti‑amyloid beta active immunotherapy ACI‑24. The therapy has been generally safe and well tolerated so far, with no amyloid‑related imaging abnormalities‑edema (ARIA‑E) observed and anti‑Abeta antibody responses detected at all dose levels with a dose response. The company is now testing an enhanced ACI‑24 formulation with an additional adjuvant in the newly initiated Cohort AD4 to further boost immunogenicity. Under its existing option and license agreement with Takeda for anti‑Abeta active immunotherapies, AC Immune received an upfront payment of $100 million and a $12 million milestone on dosing the first patients in Cohort AD4, and may earn up to approximately $2.1 billion in additional milestones plus tiered double‑digit royalties if the program advances to commercialization.
AC Immune SA director Roy Ervin Twyman received equity awards as compensation. On June 11, 2026 he was granted 16,568 restricted share units under the AC Immune SA 2016 Stock Option and Incentive Plan, increasing his holdings to 92,556 common shares, including 66,556 shares underlying outstanding restricted share units.
On the same date he also received share options over 38,889 common shares with an exercise price of $2.62 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036, giving him the right to buy the underlying shares in the future rather than reflecting an open-market purchase.
AC Immune SA director Renee Aguiar-Lucander reported equity compensation awards rather than open-market trades. On June 11, 2026, she received a restricted share unit grant covering 16,568 common shares under the AC Immune SA 2016 Stock Option and Incentive Plan.
Following this grant, 51,136 common shares are underlying her outstanding restricted share units. She was also awarded options for 38,889 common shares at an exercise price of $2.62 per share, which fully vest on June 10, 2027 and expire on June 10, 2036.
AC Immune SA interim CEO Martin Zuegel reported equity compensation awards. On June 11, 2026, he received a grant of 33,136 restricted share units under the company’s 2016 Stock Option and Incentive Plan. Following this award, he holds 71,408 common shares underlying outstanding restricted share units.
On the same date, he was also granted share options on 77,778 common shares at an exercise price of $2.6200 per share. These options will fully vest on June 10, 2027 and expire on June 10, 2036. All reported holdings are direct.